Predicting tumor outcomes in urothelial bladder carcinoma: Turning pathways into clinical biomarkers of prognosis

Expert Review of Anticancer Therapy

Volumn 8, Issue 7, 2008, Pages 1103-1110

  Ehdaie, Behfar ^a   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Biomarkers; Bladder cancer; Carcinogenesis; Cell cycle regulators; Loss of heterozygosity; Molecular markers; Prognosis; Urothelial carcinoma

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GROWTH FACTOR; MESSENGER RNA; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CELL ADHESION; CELL CYCLE REGULATION; CELL MIGRATION; CHROMOSOME ABERRATION; CLINICAL PATHWAY; DIAGNOSTIC VALUE; DISEASE COURSE; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; PREDICTION; PROGNOSIS; REVIEW; BLADDER TUMOR; CELL TRANSFORMATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 48849092710     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.7.1103     Document Type: Review

References (92)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer. J. Clin. 57(1), 43-66 (2007).
2. Beaglehole R, Irwin A, Prentice T. Changing history. The World Health Report 2004. 122 (2004).
3. Pelucchi C, Bosetti C, Negri E, Malvezzi MC, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 3(6), 327-340 (2006).
4. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. North Am. 19(3), 429-433 (1992).
5. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol. 153(6), 1823-1826; Discussion 1826-1827 (1995).
6. May M, Helke C, Nitzke T, Vogler H, Hoschke B. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol. Int. 72(2), 103-111 (2004).
7. Dalbagni G, Presti J, Reuter V et al. Genetic alterations in bladder cancer. Lancet 342(8869), 469-471 (1993).
8. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54(3), 784-788 (1994).
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
10. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J. Urol. 162(5), 1697-1701 (1999).
11. Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 69(1 Suppl.), 62-79 (2007).
12. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 66(6 Suppl. 1), 108-125 (2005).
13. Wolf H, Hojgaard K. Prognostic factors in local surgical treatment of invasive bladder cancer, with special reference to the presence of urothelial dysplasia. Cancer 51(9), 1710-1715 (1983).
14. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49 (3), 466-465; Discussion 475-477 (2006).
15. Shariat SF, Zippe C, Ludecke G et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol. 173(5), 1518-1525 (2005).
16. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol. 24(24), 3967-3972 (2006).
17. Weinberg RA Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49(14), 3713-3721(1989).
18. Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer. 31A(11), 1840-1846 (1995).
19. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4(5), 361-370 (2004).
20. Billerey C, Chopin D, Aubriot-Lorton MH et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158(6), 1955-1959 (2001).
21. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24(33), 5218-5225 (2005).
22. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J. Urol. 170(5), 1987-1993 (2003).
23. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61(4), 1265-1268 (2001).
24. van Rhijn BW, Vis AN, van der Kwast TH et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol 21(10), 1912-1921 (2003).
25. Ornitz; DM, Itoh N. Fibroblast growth factors. Genome Biol. 2, 3 (2001).
26. van Rhijn BW, Vis AN, van der Kwast TH et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21 (10), 1912-1921 (2003).
27. Zieger K, Dyrskjot L, Wiuf C et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin. Cancer Res. 11(21), 7709-7719 (2005).
28. Hernandez S, Lopez-Knowles E, Lloreta J et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin. Cancer Res. 11(15), 5444-5450 (2005).
29. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur. J. Surg. Oncol. 32(2), 231-237 (2006).
30. López-Knowles E, Hernández S, Malats N et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66(15), 7401-7404 (2006).
31. Zhang ZT, Pak J, Huang HY et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20(16), 1973-1980 (2001).
32. Jebar AH, Hurst CD, Tomlinson DC et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24(33), 5218-5225 (2005).
33. Santos LL, Amaro T, Pereira SA et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur. J. Surg. Oncol. 29(1), 74-80 (2003).
34. Yurakh AO, Ramos D, Calabuig-Firinas S et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur. Urol. 50(3), 506-515; Discussion 515 (2006).
35. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am. J. Pathol. 154(3), 721-727 (1999).
36. Stoehr R, Zietz S, Burger M et al. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur, Urol. 47(1), 58-63 (2005).
37. Obermann EC, Junker K, Stoehr R et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J. Pathol. 199(1), 50-57 (2003).
38. Chow NH, Cairns P, Eisenberger CF et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int. J. Cancer 89(6), 514-518 (2000).
39. Hartmann A, Schlake G, Zaak D et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62(3), 809-818 (2002).
40. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int. J. Oncol. 23(1), 41-48 (2003).
41. Messing EM, Young TB, Hunt VB et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 45(3), 387-96; discussion 396-397 (1995).
42. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol. 6(1), 44-55 (2005).
43. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70(6), 923-935 (1992).
44. Cordon-Cardo C. Molecular alterations in bladder cancer. Cancer Surv. 32, 115-131 (1998).
45. Ortoft TF, Wolf H. Molecular alterations in bladder cancer. Urological Res. 26(4), 223 (1998).
46. Cordon-Cardo C, Dalbagni G, Saez GT et al p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer. 56(3), 347-353 (1994).
47. Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur. Urol. 32(2), 229-236 (1997).
48. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331(19), 1259-1264 (1994).
49. Gontero P, Casetta G, Zitella A et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur. Urol. 38(3), 287-296 (2000).
50. Lacombe L, Dalbagni G, Zhang ZF et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome. J. Clin. Oncol. 14(10), 2646-2652 (1996).
51. Lianes P, Charytonowicz E, Cordon-Cardo C et al. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin. Cancer Res. 4(5), 1267-1271 (1998).
52. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21 Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur. Urol. 45(5), 606-612 (2004).
53. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cydin D3), proliferation index, and dinicopathologic parameters. Am. J. Clin. Pathol. 122(3), 444-452 (2004).
54. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6(9), 678-686 (2005).
55. Schmitz-Drager BJ, Goebell PJ, Heydthausen M. p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go? Urol. Oncol. 5(5), 204-210 (2000).
56. Stein JP, Ginsberg DA, Grossfeld GD et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl Cancer Inst. 90(14), 1072-1079 (1998).
57. Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22(6), 1014-1024 (2004).
58. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol. 177(2), 481-487; discussion 487 (2007).
59. Goodrich DW, Wang NP, Qian YW et al. The retinoblastoma gene product regulates progression through the G1 phase of the Cell cycle. Cell 67(2), 293-302 (1991).
60. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The F2F transcription factor is a cellular target for the RB protein. Cell 65(6), 1053-1061 (1991).
61. Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin. Genitourin. Cancer 5(1), 67-77 (2006).
62. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22(6), 1007-1013 (2004).
63. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58(6), 1090-1094 (1998).
64. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 59(14), 3512-3517 (1999).
65. Garcia del Muro X Torregrosa A, Munoz J et al. Prognostic value of the expression of E-cadherin and α-catenin in bladder cancer. Eur. J. Cancer. 36(3), 357-362 (2000).
66. Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J. Urol. 170(6 Pt 1), 2248-2252 (2003).
67. Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA et al. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br. J. Cancer 83(2), 209-214 (2000).
68. Shariat SF, Pahlavan S, Baseman AG et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 57(1), 60-65 (2001).
69. McKnight JJ, Gray SB, O'Kane HF et al. Apoptosis and chemotherapy for bladder cancer. J. Urol. 173, 683-690 (2005).
70. Svatek RS, Herman MP, Lotan Y et al. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106, 1701-1707 (2006).
71. Karam JA, Lotan Y, Karakiewicz PL et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 8(128), 128-136 (2007).
72. Kong G, Shin KY, Oh YH et al. Bcl-2 and p53 expression in invasive bladder cancers. Acta Oncol. 37, 715-720 (1998).
73. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285, 324-328 (2001).
74. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324(1), 1-8 (1991).
75. Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst. 87(21), 1603-1612 (1995).
76. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J. Urol. 166(4), 1275-1279 (2001).
77. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int. 98, 1090-1093 (2006).
78. Chambers AF, MacDonald IC, Schmidt EE et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 14(4), 279-301 (1995).
79. Kamai T, Tsujii T, Arai K et al. Significant association of Rho/ ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9(7), 2632-2641 (2003).
80. Gildea JJ, Seraj MJ, Oxford G et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 62(22), 6418-6423 (2002).
81. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin. Cancer Res. 10(11), 3800-3806 (2004).
82. Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl. 1), 64-74 (2005).
83. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24(5), 778-789 (2006).
84. Modlich O, Prisack HB, Pitschke G et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res. 10(10), 3410-3421 (2004).
85. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrskjot L, Orntoft TF. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br. J. Cancer. 93(10), 1182-1190 (2005).
86. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003).
87. Thykjaer T, Workman C, Orntoft TF et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 61, 2492-2499 (2001).
88. Wang S, El-Deiry WS. The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat. Res. 119, 175-187 (2004).
89. McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther. 11(6), 497-503 (2004).
90. Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J. Urol. 24(5), 565-578 (2006).
91. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24(35), 5552-5564 (2006).
92. Titus B, Frierson HF Jr, Conaway M et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 65(16), 7320-7327 (2005).